Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France

IMPORTANCE: Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated. OBJECTIVE: To describe the temporal evolutio...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Neurol
Main Authors: Vukusic, Sandra, Rollot, Fabien, Casey, Romain, Pique, Julie, Marignier, Romain, Mathey, Guillaume, Edan, Gilles, Brassat, David, Ruet, Aurélie, De Sèze, Jérôme, Maillart, Elisabeth, Zéphir, Hélène, Labauge, Pierre, Derache, Nathalie, Lebrun-Frenay, Christine, Moreau, Thibault, Wiertlewski, Sandrine, Berger, Eric, Moisset, Xavier, Rico-Lamy, Audrey, Stankoff, Bruno, Bensa, Caroline, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Vaillant, Mathieu, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean-Philippe, Tourbah, Ayman, Guennoc, Anne-Marie, Hankiewicz, Karolina, Patry, Ivania, Nifle, Chantal, Maubeuge, Nicolas, Labeyrie, Céline, Vermersch, Patrick, Laplaud, David-Axel
Format: Artigo
Language:Inglês
Published: American Medical Association 2019
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6724170/
https://ncbi.nlm.nih.gov/pubmed/31479149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.2670
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items